LSEG Stock Analysis: 44% Upside Case for 2026 – Institutional Research Note
This LSEG stock analysis examines London Stock Exchange Group plc (LON: LSEG) following a severe AI-fear-driven selloff that has created what our proprietary Wealth…
Sector
Equities
Every equity analysis published by Moschovakis Capital, scored on the 100-point Wealth Preservation framework. Coverage spans global markets and sectors, and each thesis is backed by real capital in a publicly visible eToro portfolio. The framework judges capital preservation before upside, so a high-quality business at the wrong price scores no better than a weak one.
SMCI Stock Analysis: 10 Disqualifying Factors Exposed for 2026 – Institutional Research Note
This SMCI stock analysis represents a comprehensive institutional equity research note published by the Moschovakis Capital Wealth Preservation Research Division. Our mandate is capital…
Doximity Stock Analysis: 70% Upside Case for 2026 – Institutional Research Note
This Doximity stock analysis identifies what we consider one of the most compelling risk-adjusted opportunities in healthcare technology today. At $33.50 per share, DOCS…
Molina Healthcare Stock Analysis: 133% Upside Case for 2031 – Institutional Research Note
This Molina Healthcare stock analysis identifies one of the most compelling asymmetric opportunities in the managed care sector for 2026. At $118 per share…
eToro Stock Analysis: 53% Upside Case for 2026 – Institutional Research Note
Executive Summary Bottom Line Up Front Thesis: eToro Group (NASDAQ: ETOR) is a profitable, debt-free social trading platform trading at just 6.3x EV/FCF following…
UBER Stock Analysis: 22% Upside Case for 2026 – Institutional Research Note
Executive Summary UBER stock analysis confirms a compelling risk-adjusted opportunity following the Q4 2024 earnings selloff. This institutional research note dissects Uber Technologies’ transformation…
QCOM Stock Analysis: 24% Upside Potential for 2026 – Institutional Research Note
Executive Summary QCOM stock analysis reveals one of the most compelling asymmetric opportunities in the semiconductor sector for 2026. This research note examines Qualcomm…
Novo Nordisk Stock Analysis: 41% Upside Case for 2026 – Institutional Research Note
Executive Summary Novo Nordisk stock analysis reveals what institutional investors recognize as a textbook asymmetric opportunity in global healthcare. The GLP-1 market leader, with…
BAM Stock Analysis: 21% Upside Case for 2026 – Institutional Research Note
Executive Summary Metric Value Recommendation BUY ON WEAKNESS Current Price $52.04 Fair Value (Base Case) $63.00 Margin of Safety 21.1% Target Entry Zone $46.00…
CRVL Stock Analysis: 36% Upside Potential for 2026 – Institutional Research Note
Executive Summary CRVL stock analysis reveals an exceptional wealth preservation opportunity in CorVel Corporation—a technology-enabled claims management company trading at a 47% discount from…